A Phase I/Ib Study of Lenvatinib and Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Lenvatinib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 02 Dec 2019 Planned number of patients changed from 16 to 22.
- 04 May 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 03 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.